DOI:

Tryton Side-Branch Stent

Aaron V. Kaplan1,2*, M.D; H. Richard Davis2

Description

The Tryton Side-Branch Stent™ is a slotted tube balloon deployable stent with a modular design comprise of three zones: Distal (Side-Branch) Zone, Central (Transition) Zone and Proximal (Main Vessel) Zone (Figure 1).

Figure 1. Schematic representing the Tryton Side-Branch Stent showing three zones: Distal (Side-Branch) Zone, Central (Transition) Zone and Proximal (Main Vessel) Zone. When positioned correctly within the vasculture the Side-Branch Zone resides in the side-branch, Transition Zone at the side-branch origin and the Main Vessel Zone in the main vessel proximal to the side-branch origin.

Tryton performs like a standard high-performance workhorse stent, i.e., balloon expandable, tracking over a single wire and axially oriented without the need for rotational orientation. The Tryton is simply tracked over a guidewire placed in the side-branch, such that the transition zone is at the side-branch origin. To insure precise delivery, the Tryton Side-Branch Stent is mounted on a balloon with four shaft markers, 2 standard proximal/distal stent markers, and 2 additional markers delineating the Transition Zone. The Tryton Stent is deployed after which the guidewire initially placed in the side-branch is repositioned into the distal main vessel. The Tryton stent is compatible with any standard workhorse stent (bare metal or DES), which is tracked into the Main Vessel Zone of the Tryton Stent and between specially designed fronds exiting into the distal main vessel stent (Figure 2).

Figure 2. Schematic representing the spacial relationship between the Tryton Side-Branch Stent (deployed) with an undeployed main vessel stent. The distal end of the main vessel stent has been tracked through the proximal Main Vessel Zone of the Tryton Stent, between the specially designed fronds and into the distal main vessel.

The main vessel stent is deployed after which a kissing balloon inflation is performed. Employing this strategy provides a means to definitively treat bifurcation lesions with similar coverage and hoop strength currently available with state of the art stents used in straight lesions (Figure 3).

Figure 3. Photograph of a Tryton Side-Branch Stent deployed in a plexiglass model in combination with a Cypher Stent (Cordis/ Johnson&Johnson, Miami, FL) using the protocol outlined within main text.

History

Tryton Medical, Inc. is a privately held company with offices in Newton, Massachusetts, USA founded to develop devices to treat bifurcation lesions within the coronary, cerebral and peripheral circulations.

Volume 2 Number 2
Aug 20, 2006
Volume 2 Number 2
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-24-00052 Nov 18, 2024
Low-flow, low-gradient aortic stenosis: an understanding is still a long way off
Webb J and Offen S
free

Debate

10.4244/EIJ-E-24-00054 Nov 18, 2024
TAVI patients with bystander coronary artery disease should receive PCI: pros and cons
Rodés-Cabau J et al
free

EAPCI Column

Nov 18, 2024
EAPCI at PCR London Valves 2024
free

Original Research

10.4244/EIJ-D-24-00442 Nov 18, 2024
Long-term survival after TAVI in low-flow, low-gradient aortic valve stenosis
Cardaioli F et al

Original Research

10.4244/EIJ-D-24-00367 Nov 18, 2024
Feasibility of redo-TAVI in the self-expanding ACURATE neo2 valve: a computed tomography study
Bieliauskas G et al
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved